CCT
ABBV icon

Capital City Trust’s AbbVie ABBV Stock Holding History

Capital City Trust’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.45M Sell
34,263
-534
-2% -$118K 1.7% 15
2025
Q4 		$7.95M Sell
34,797
-590
-2% -$134K 1.77% 16
2025
Q3 		$8.19M Sell
35,387
-2,229
-6% -$454K 2% 13
2025
Q2 		$6.98M Buy
37,616
+175
+0.5% +$32.5K 1.81% 15
2025
Q1 		$7.84M Buy
37,441
+453
+1% +$88.1K 2.15% 11
2024
Q4 		$6.57M Buy
36,988
+377
+1% +$69.3K 1.64% 16
2024
Q3 		$7.23M Buy
36,611
+611
+2% +$114K 1.79% 13
2024
Q2 		$6.17M Sell
36,000
-309
-0.9% -$51.2K 1.68% 14
2024
Q1 		$6.61M Sell
36,309
-1,123
-3% -$194K 1.84% 15
2023
Q4 		$5.8M Buy
37,432
+585
+2% +$85.3K 1.73% 15
2023
Q3 		$5.49M Sell
36,847
-3,662
-9% -$538K 1.82% 14
2023
Q2 		$5.46M Sell
40,509
-1,499
-4% -$220K 1.7% 14
2023
Q1 		$6.69M Buy
42,008
+335
+0.8% +$51.2K 2.13% 7
2022
Q4 		$6.73M Sell
41,673
-445
-1% -$68.2K 2.22% 7
2022
Q3 		$5.65M Buy
42,118
+241
+0.6% +$34.6K 1.98% 9
2022
Q2 		$6.41M Sell
41,877
-175
-0.4% -$26.7K 2.09% 8
2022
Q1 		$6.82M Sell
42,052
-235
-0.6% -$34.1K 1.97% 10
2021
Q4 		$5.73M Buy
42,287
+144
+0.3% +$17K 1.63% 16
2021
Q3 		$4.55M Buy
42,143
+512
+1% +$58.5K 1.41% 21
2021
Q2 		$4.69M Buy
41,631
+653
+2% +$73.5K 1.42% 20
2021
Q1 		$4.43M Buy
40,978
+1,142
+3% +$122K 1.41% 23
2020
Q4 		$4.27M Buy
39,836
+712
+2% +$68.4K 1.49% 20
2020
Q3 		$3.43M Buy
39,124
+1,672
+4% +$157K 1.26% 24
2020
Q2 		$3.68M Buy
37,452
+4,683
+14% +$412K 1.41% 24
2020
Q1 		$2.5K Buy
32,769
+652
+2% +$55.5K 1.12% 28
2019
Q4 		$2.84M Buy
32,117
+637
+2% +$52.9K 1.07% 34
2019
Q3 		$2.38M Buy
31,480
+746
+2% +$51.1K 1.05% 36
2019
Q2 		$2.23M Buy
30,734
+337
+1% +$26.5K 0.92% 38
2019
Q1 		$2.45M Buy
30,397
+55
+0.2% +$4.5K 1.03% 33
2018
Q4 		$2.8M Buy
30,342
+364
+1% +$32K 1.27% 24
2018
Q3 		$2.84M Buy
29,978
+582
+2% +$55.2K 1.14% 29
2018
Q2 		$2.72M Buy
29,396
+210
+0.7% +$20.5K 1.16% 26
2018
Q1 		$2.76M Sell
29,186
-1,167
-4% -$128K 1.19% 26
2017
Q4 		$2.94K Buy
30,353
+2,123
+8% +$200K 1.2% 24
2017
Q3 		$2.05M Hold
28,230
– – 0.8% 41
2017
Q2 		$2.05M Buy
28,230
+1,847
+7% +$124K 0.8% 41
2017
Q1 		$1.72M Buy
26,383
+1,647
+7% +$104K 0.68% 50
2016
Q4 		$1.55M Buy
24,736
+2,320
+10% +$142K 0.62% 53
2016
Q3 		$1.41M Buy
22,416
+843
+4% +$54.6K 0.57% 53
2016
Q2 		$1.34M Buy
21,573
+2,023
+10% +$123K 0.54% 53
2016
Q1 		$1.12M Buy
19,550
+1,055
+6% +$58.8K 0.45% 56
2015
Q4 		$1.1M Sell
18,495
-145
-0.8% -$8.35K 0.45% 56
2015
Q3 		$1.01M Buy
18,640
+50
+0.3% +$3.25K 0.43% 59
2015
Q2 		$1.25M Buy
18,590
+1,084
+6% +$70.8K 0.51% 56
2015
Q1 		$1.02M Sell
17,506
-210
-1% -$12.7K 0.42% 60
2014
Q4 		$1.16M Hold
17,716
– – 0.47% 55
2014
Q3 		$1.02M Buy
17,716
+1,016
+6% +$56.4K 0.43% 57
2014
Q2 		$942K Buy
16,700
+385
+2% +$20.2K 0.39% 62
2014
Q1 		$839K Buy
16,315
+400
+3% +$20.2K 0.36% 61
2013
Q4 		$840K Sell
15,915
-55
-0.3% -$2.7K 0.36% 60
2013
Q3 		$714 Buy
15,970
+830
+5% +$36.8K 0.32% 63
2013
Q2 		$626K Buy
+15,140
New +$662K 0.28% 64

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital City Trust's ABBV Position: Q1 2026 in Review

Capital City Trust reduced its AbbVie (ABBV) stake by 1.5% in Q1 2026, selling an estimated $118K and leaving 34,263 shares worth $7.45M. The position accounts for 1.7% of the portfolio, ranked #15.

Capital City Trust first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $8.19M in Q3 2025. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Capital City Trust held 34,263 shares of AbbVie worth $7.45M as of Q1 2026.
  • Capital City Trust sold 534 AbbVie shares in Q1 2026, an estimated $118K.
  • AbbVie made up 1.7% of Capital City Trust's portfolio in Q1 2026, its #15 holding.
  • Capital City Trust first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
  • Capital City Trust's AbbVie position peaked at $8.19M in Q3 2025.
  • 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Capital City Trust's 13F filing for Q1 2026, filed 1 May 2026.